Skip to main content

Research Repository

Advanced Search

Outputs (6)

Immunocompromised children and young people are at no increased risk of severe COVID-19 (2021)
Journal Article
Chappell, H., Patel, R., Driessens, C., Tarr, A. W., Irving, W. L., Tighe, P. J., …de Graaf, H. (2022). Immunocompromised children and young people are at no increased risk of severe COVID-19. Journal of Infection, 84(1), 31-39. https://doi.org/10.1016/j.jinf.2021.11.005

Objectives: We aimed to prospectively describe the incidence and clinical spectrum of SARS-CoV-2 infection in immunocompromised paediatric patients in the UK. Methods: From March 2020 to 2021 weekly questionnaires were sent to immunocompromised paedi... Read More about Immunocompromised children and young people are at no increased risk of severe COVID-19.

An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development (2021)
Journal Article
Salas, J. H., Urbanowicz, R. A., Guest, J. D., Frumento, N., Figueroa, A., Clark, K. E., …Bailey, J. R. (2022). An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. Gastroenterology, 162(2), 562-574. https://doi.org/10.1053/j.gastro.2021.10.005

Background & Aims: Development of a prophylactic hepatitis C virus (HCV) vaccine will require accurate and reproducible measurement of neutralizing breadth of vaccine-induced antibodies. Currently available HCV panels may not adequately represent the... Read More about An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development.

Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection (2021)
Journal Article
Urbanowicz, R. A., Tsoleridis, T., Jackson, H. J., Cusin, L., Duncan, J. D., Chappell, J. G., …Ollivere, B. J. (2021). Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Science Translational Medicine, 13(609), Article eabj0847. https://doi.org/10.1126/scitranslmed.abj0847

Understanding the impact of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the response to vaccination is a priority for responding to the coronavirus disease 2019 (COVID-19) pandemic. In particular, it is necess... Read More about Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection.

Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination (2021)
Journal Article
Allen, C. M., Ramsamy, S., Tarr, A. W., Tighe, P. J., Irving, W. L., Tanasescu, R., & Evans, J. R. (2021). Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination. Annals of Neurology, 90(2), 315-318. https://doi.org/10.1002/ana.26144

Although SARS-CoV-2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain–Barré syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford–AstraZeneca SARS-CoV-2 vaccine. This rare neurol... Read More about Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination.